scholarly journals Prognostic Value of Homotypic Cell Internalization by Nonprofessional Phagocytic Cancer Cells

2015 ◽  
Vol 2015 ◽  
pp. 1-14 ◽  
Author(s):  
Manuela Schwegler ◽  
Anna M. Wirsing ◽  
Hannah M. Schenker ◽  
Laura Ott ◽  
Johannes M. Ries ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Tissue Sample ◽  
Apoptotic Cell ◽  
Treatment Strategies ◽  
Tissue Microarrays ◽  
Cell Internalization ◽  
Cell Structures

Background. In this study, we investigated the prognostic role of homotypic tumor cell cannibalism in different cancer types.Methods. The phenomenon of one cell being internalized into another, which we refer to as “cell-in-cell event,” was assessed in 416 cases from five head and neck cancer cohorts, as well as one anal and one rectal cancer cohort. The samples were processed into tissue microarrays and immunohistochemically stained for E-cadherin and cleaved caspase-3 to visualize cell membranes and apoptotic cell death.Results. Cell-in-cell events were found in all of the cohorts. The frequency ranged from 0.7 to 17.3 cell-in-cell events per mm2. Hardly any apoptotic cells were found within the cell-in-cell structures, although apoptotic cell rates were about 1.6 to two times as high as cell-in-cell rates of the same tissue sample. High numbers of cell-in-cell events showed adverse effects on patients’ survival in the head and neck and in the rectal cancer cohorts. In multivariate analysis, high frequency was an adverse prognostic factor for overall survival in patients with head and neck cancer (p=0.008).Conclusion. Cell-in-cell events were found to predict patient outcomes in various types of cancer better than apoptosis and proliferation and might therefore be used to guide treatment strategies.

How Do Head and Neck Cancer Patients Prioritize Treatment Outcomes Before Initiating Treatment?

2000 ◽  
Vol 18 (4) ◽  
pp. 877-877 ◽  
Author(s):  
Marcy A. List ◽  
John Stracks ◽  
Laura Colangelo ◽  
Pamela Butler ◽  
Natasha Ganzenko ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Treatment Effects ◽  
Performance Status ◽  
Treatment Strategies ◽  
Individual Variability ◽  
Lower Priority ◽  
Disease Characteristics

PURPOSE: To determine, pretreatment, how head and neck cancer (HNC) patients prioritize potential treatment effects in relationship to each other and to survival and to ascertain whether patients’ preferences are related to demographic or disease characteristics, performance status, or quality of life (QOL). PATIENTS AND METHODS: One hundred thirty-one patients were assessed pretreatment using standardized measures of QOL (Functional Assessment of Cancer Therapy-Head and Neck) and performance (Performance Status Scale for Head and Neck Cancer). Patients were also asked to rank a series of 12 potential HNC treatment effects. RESULTS: Being cured was ranked top priority by 75% of patients; another 18% ranked it second or third. Living as long as possible and having no pain were placed in the top three by 56% and 35% of patients, respectively. Items that were ranked in the top three by 10% to 24% of patients included those related to energy, swallowing, voice, and appearance. Items related to chewing, being understood, tasting, and dry mouth were placed in the top three by less than 10% of patients. Excluding the top three rankings, there was considerable variability in ratings. Rankings were generally unrelated to patient or disease characteristics, with the exception that cure and living were of slightly lower priority and pain of higher priority to older patients compared with younger patients. CONCLUSION: The data suggest that, at least pretreatment, survival is of primary importance to patients, supporting the development of aggressive treatment strategies. In addition, results highlight individual variability and warn against making assumptions about patients’ attitudes vis-à-vis potential outcomes. Whether patients’ priorities will change as they experience late effects is currently under investigation.

scholarly journals Advances in biomarkers and treatment strategies for HPV-associated head and neck cancer

Oncoscience ◽  
2018 ◽  
Vol 5 (5-6) ◽  
pp. 140-141 ◽  
Author(s):  
Cassie Pan ◽  
Wendell G. Yarbrough ◽  
Natalia Issaeva
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Treatment Strategies

scholarly journals CD44s Induces miR-629-3p Expression in Association with Cisplatin Resistance in Head and Neck Cancer Cells

Cancers ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 856
Author(s):  
Junichiro Chikuda ◽  
Kurataka Otsuka ◽  
Iwao Shimomura ◽  
Kagenori Ito ◽  
Hiroaki Miyazaki ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Target Genes ◽  
Cisplatin Resistance ◽  
Apoptotic Cell ◽  
Standard Form ◽  
Therapeutic Effects ◽  
Gene Expressions

Cisplatin (cis-diamminedichloroplatinum II [CDDP] ) is a well-known chemotherapeutic drug that has been used for the treatment of various types of human cancers, including head and neck cancer. Cisplatin exerts anticancer effects by causing DNA damage, replication defects, transcriptional inhibition, cell cycle arrest, and the induction of apoptosis. However, drug resistance is one of the most serious problems with cancer chemotherapy, and it causes expected therapeutic effects to not always be achieved. Here, we analyzed global microRNA (miRNA) expression in CD44 standard form (CD44s)-expressing SAS cells, and we identified miR-629-3p as being responsible for acquiring anticancer drug resistance in head and neck cancer. The introduction of miR-629-3p expression inhibited apoptotic cell death under cisplatin treatment conditions, and it promoted cell migration. Among the computationally predicted target genes of miR-629-3p, we found that a number of gene expressions were suppressed by the transfection with miR-629-3p. Using a xenografting model, we showed that miR-629-3p conferred cisplatin resistance to SAS cells. Clinically, increased miR-629-3p expression tended to be associated with decreased survival in head and neck cancer patients. In conclusion, our data suggest that the increased expression of miR-629-3p provides a mechanism of cisplatin resistance in head and neck cancer and may serve as a therapeutic target to reverse chemotherapy resistance.

A History of Innovations in the Diagnosis and Treatment of Oral and Head and Neck Cancer

2019 ◽  
Vol 98 (5) ◽  
pp. 489-497 ◽  
Author(s):  
P.J. Polverini ◽  
M.W. Lingen
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Progression ◽  
Neck Cancer ◽  
New Technologies ◽  
Treatment Strategies ◽  
Disease Process ◽  
Treatment Protocols ◽  
Multistep Process ◽  
Etiological Agents

Historical records as far back as 3000 BCE show that oral and head and neck cancer was a disease process well known to Egyptian physicians. Luminaries such as Hippocrates, Galen, Pott, and Virchow were instrumental in shaping our understanding of the etiology and pathogenesis of cancer. During the 20th century, evidence-based medicine catalyzed the development of rigorous science-based diagnostic and treatment protocols. The use of surgery, therapeutic radiation, and chemotherapy as single-treatment agents or in combination with one another gradually emerged as the preferred approach to cancer therapy. The recognition of tobacco, alcohol, and human papillomavirus as etiological agents in oral and head and neck cancer prompted the development of new diagnostic aids and treatment strategies to mitigate cancer progression. More in-depth mechanistic insights into the multistep process of oral and head and neck cancer were made possible by the use of the hamster buccal pouch and mouse models. New technologies, such as the sequencing of the human genome, metabolomics, and proteomics, have provided the foundation for what we today call precision medicine. The future success of tailored medical treatment for cancer patients will depend on the discovery of new druggable targets with improved therapeutic efficacy. As the precision and sensitivity of existing tools for prevention and risk assessment improve, greater accuracy will be achieved in predicting health outcomes.

Single-cell microinjection of cytochromec can result in gap junction-mediated apoptotic cell death of bystander cells in head and neck cancer

Head & Neck ◽  
2005 ◽  
Vol 27 (9) ◽  
pp. 794-800 ◽  
Author(s):  
Douglas K. Frank ◽  
Bozena Szymkowiak ◽  
Olgica Josifovska-Chopra ◽  
Torahiko Nakashima ◽  
Kathleen W. Kinnally
Keyword(s):  
Cell Death ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Gap Junction ◽  
Single Cell ◽  
Neck Cancer ◽  
Apoptotic Cell ◽  
Apoptotic Cell Death ◽  
Bystander Cells

Evaluation and Management of the Unknown Primary Carcinoma of the Head and Neck

2008 ◽  
Vol 6 (10) ◽  
pp. 1068-1075 ◽  
Author(s):  
Chad E. Galer ◽  
Merrill S. Kies
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Clinical Presentation ◽  
Treatment Strategies ◽  
Clinical Problem ◽  
Unknown Primary ◽  
Multidisciplinary Teams ◽  
Primary Origin ◽  
Unknown Primary Carcinoma

Squamous cell carcinoma of unknown primary origin in the head and neck is encountered as a recurring clinical problem in head and neck cancer clinics, affecting 3% to 25% of patients. This article describes the clinical presentation, appropriate evaluation, and treatment strategies for this important subgroup. Treatment—best carried out with multidisciplinary teams of specialists experienced in the care of head and neck cancer patients—is curative for most of these patients.

Sign in / Sign up

Export Citation Format

Share Document